title: Effects of hemodialysis on plasma protein binding of bepridil.
abstract: The effects of end-stage renal disease (ESRD) and hemodialysis on the in vitro plasma protein binding of bepridil hydrochloride were investigated. The possible influence of bepridil metabolites on bepridil-protein binding in ESRD patients was also examined. Plasma samples were obtained from six patients with ESRD. Bepridil-plasma protein binding was measured by microequilibrium dialysis after addition of freshly prepared bepridil-14C (239 microCi/mg) at a final concentration of 2 micrograms/mL. The percentage of free bepridil in peripheral venous samples drawn on a nondialysis day was lower (i.e., binding was greater) in the patients with ESRD relative to previous observations in healthy subjects (0.15% +/- 0.04% versus 0.31% +/- 0.05% (mean +/- SD). The plasma concentrations of alpha-1-acid glycoprotein (AAG), the principal bepridil binding protein, were also higher in ESRD patients (110 +/- 32 mg/dL) than previously reported in healthy subjects. Although hemodialysis resulted in significant increases in AAG, total protein, and albumin concentrations, no significant difference in bepridil-plasma protein binding was detected between predialysis and postdialysis peripheral venous samples in the presence (0.16 versus 0.18) or absence (0.20 versus 0.17) of bepridil metabolites. The percentage of free bepridil in plasma from both the arterial and venous limbs of the dialyzer during hemodialysis (means of free bepridil ranged from 0.24-0.28%) was higher than in samples drawn from a peripheral vein. This displacement of bepridil from its binding sites as blood passes through the dialyzer may have been owing to the presence of high local concentrations of plasticizers. Confirmation of this hypothesis will require further investigation.
authors.affiliation: Department of Drug Metabolism, R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
authors.forename: J F
authors.initials: JF
authors.lastname: Pritchard
authors.forename: G R
authors.initials: GR
authors.lastname: Matzke
authors.forename: J A
authors.initials: JA
authors.lastname: Opsahl
authors.forename: C E
authors.initials: CE
authors.lastname: Halstenson
authors.forename: R K
authors.initials: RK
authors.lastname: Nayak
mesh_terms: D000328:Adult; D015764:Bepridil / Q000097:blood*; D001798:Blood Proteins / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008875:Middle Aged; D009961:Orosomucoid / Q000378:metabolism; D011485:Protein Binding; D006435:Renal Dialysis; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D001798:Blood Proteins; D009961:Orosomucoid; D012709:Serum Albumin; D015764:Bepridil; D003404:Creatinine